These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20187239)

  • 1. Parkinson's disease: 10 years of progress, 1997-2007.
    Fahn S
    Mov Disord; 2010; 25 Suppl 1():S2-14. PubMed ID: 20187239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical measures of progression in Parkinson's disease.
    Poewe W
    Mov Disord; 2009; 24 Suppl 2():S671-6. PubMed ID: 19877235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease.
    Hatano T; Kubo S; Sato S; Hattori N
    J Neurochem; 2009 Dec; 111(5):1075-93. PubMed ID: 19780902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the genetics of Parkinson's disease.
    Rosner S; Giladi N; Orr-Urtreger A
    Acta Pharmacol Sin; 2008 Jan; 29(1):21-34. PubMed ID: 18158863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Milestones in Parkinson's disease--clinical and pathologic features.
    Halliday G; Lees A; Stern M
    Mov Disord; 2011 May; 26(6):1015-21. PubMed ID: 21626546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies for Parkinson's disease based on data derived from genetic research.
    Riess O; Berg D; Krüger R; Schulz JB
    J Neurol; 2003 Feb; 250 Suppl 1():I3-10. PubMed ID: 12761628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroimaging of nonmotor features of Parkinson's disease.
    Deblieck C; Wu AD
    Rev Neurol Dis; 2008; 5(3):125-33. PubMed ID: 18838952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontiers in the surgical treatment of Parkinson's disease.
    Remple MS; Sarpong Y; Neimat JS
    Expert Rev Neurother; 2008 Jun; 8(6):897-906. PubMed ID: 18505355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study.
    Taylor CA; Saint-Hilaire MH; Cupples LA; Thomas CA; Burchard AE; Feldman RG; Myers RH
    Am J Med Genet; 1999 Dec; 88(6):742-9. PubMed ID: 10581500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-environment interactions in Parkinson's disease.
    Ross CA; Smith WW
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S309-15. PubMed ID: 18267256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's at risk syndrome: can Parkinson's disease be predicted?
    Stern MB; Siderowf A
    Mov Disord; 2010; 25 Suppl 1():S89-93. PubMed ID: 20187248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.
    Sun F; Kanthasamy A; Anantharam V; Kanthasamy AG
    Pharmacol Ther; 2007 Jun; 114(3):327-44. PubMed ID: 17521740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.